Modeling the cost-effectiveness of doubling atorvastatin's dose versus adding niacin ER

Formulary

Volumn 36, Issue 10, 2001, Pages 730-746

  Olson, B M ^a   Malone, D C ^a   Armstrong, E P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUCED DISEASE; DRUG POTENTIATION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MODEL; REVIEW; SUSTAINED DRUG RELEASE;

EID: 0034781360     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Primer on medical decision analysis: Part 1 - Getting started
2. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
3. The Lipid Treatment Assessment Project (LTAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
4. Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment
5. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
6. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia
7. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia
8. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin
9. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated
10. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
11. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
12. Niacin revisited: Clinical observations on an important but underutilized drug
13. Evaluating niacin in its various forms
14. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus niacin in the management of hyperlipidemia
15. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
16. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
17. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
18. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia
19. Combination drug therapy for hypercholesterolemia
20. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
21. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial
22. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
23. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study
24. Determining unit cost values for health care resources in pharmacoeconomic studies